CODEXIS, INC.CDXSEarnings & Financial Report
Nasdaq · protein engineering
Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.
NextMar 30, 2026
CDXS Q3 2025 Key Financial Metrics
Revenue
$8.6M
Gross Profit
$6.1M
Operating Profit
$-18.9M
Net Profit
$-19.6M
Gross Margin
71.3%
Operating Margin
-220.3%
Net Margin
-228.1%
YoY Growth
-33.0%
EPS
$-0.22
Financial Flow
CODEXIS, INC. Q3 2025 Financial Summary
CODEXIS, INC. reported revenue of $8.6M for Q3 2025, with a net profit of $-19.6M (-228.1% margin). Cost of goods sold was $2.5M, operating expenses totaled $25.1M.
Key Financial Metrics
| Total Revenue | $8.6M |
|---|---|
| Net Profit | $-19.6M |
| Gross Margin | 71.3% |
| Operating Margin | -220.3% |
| Report Period | Q3 2025 |
CODEXIS, INC. Annual Revenue by Year
CODEXIS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $59.3M).
| Year | Annual Revenue |
|---|---|
| 2024 | $59.3M |
| 2023 | $70.1M |
| 2022 | $138.6M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26.6M | $17.1M | $8.0M | $12.8M | $21.5M | $7.5M | $15.3M | $8.6M |
| YoY Growth | -12.6% | 31.5% | -62.6% | 38.3% | -19.2% | -55.8% | 92.1% | -33.0% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $136.6M | $149.6M | $132.0M | $148.2M | $149.0M | $128.9M | $138.2M | $124.0M |
| Liabilities | $49.9M | $70.3M | $70.6M | $74.8M | $82.1M | $79.3M | $82.6M | $85.4M |
| Equity | $86.6M | $79.3M | $61.4M | $73.4M | $66.9M | $49.6M | $55.6M | $38.5M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-11.0M | $-7.8M | $-12.2M | $-13.0M | $-16.5M | $-13.8M | $-18.0M | $-7.7M |